Medpage Today on MSN2d
Which High-Risk Patients Should Get the RSV Vaccine?The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...
GlobalData on MSN3d
Moderna’s mRESVIA vaccine gains Health Canada approvalModerna has received Health Canada's approval for its respiratory syncytial virus messenger ribonucleic acid (mRNA) vaccine ...
Image by Arek Socha from Pixabay November 12, 2024 - By Lorna Fernandes - As fall arrives, so does respiratory syncytial ...
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...
Respiratory syncytial virus (RSV) caused significant hospitalizations and severe outcomes in adults, especially those aged 75 ...
Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.
Moderna reported a surprising third-quarter profit on Thursday, driven by cost reductions and stronger-than-expected sales of ...
Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...
Health Canada approves Moderna’s RSV vaccine, mRESVIA for adults aged 60 years and older: Cambridge, Massachusetts Monday, November 11, 2024, 12:00 Hrs [IST] Moderna, Inc., a le ...
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringes Canada is the fourth jurisdiction to approve mRESVIA ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback